Search Results - M. Matasar

251 | HIGH COMPLETE RESPONSE RATES AND DIFFERENTIAL TOXICITY OF MOSUNETUZUMAB AND LENALIDOMIDE IN PREVIOUSLY UNTREATED FOLLICULAR AND MARGINAL ZONE LYMPHOMA by A. J. Olszewski, M. Matasar, S. F. Huntington, T. Ollila, A. Pelcovits, Y. K. Tiger, J. L. Reagan, A. D. Chorzalska, J. Morgan, M. Pardo, J. McMahon, I. Yakirevich, S. Donnelly, C. Carmody, F. DAllessandro, C. Milrod, P. M. Dubielecka

Get full text

7 | POLATUZUMAB VEDOTIN, RITUXIMAB, GEMCITABINE AND OXALIPLATIN (POLA‐R‐GEMOX) FOR RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): PHASE III POLARGO TRIAL by J. Sancho, Z. Li, T. P. Vassilakopoulos, A. Viardot, A. McMillan, M. Sinan Dal, J. Pereira, J. S. Kim, L. Qiu, C. L. Batlevi, R. Ibrahim, J. Hernandez, B. McCall, Y. Jiang, M. Yan, W. Harris, L. Musick, C. Haioun, M. Matasar

Get full text

236 | MOSUNETUZUMAB DEMONSTRATES DURABLE CLINICAL BENEFIT IN PATIENTS WITH COMPLETE RESPONSE AND HIGH‐RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA by C. Y. Cheah, N. L. Bartlett, M. Matasar, S. J. Schuster, S. Assouline, L. H. Sehn, J. Kuruvilla, P. Giri, M. Shadman, M. Ku, G. Hess, G. P. Gregory, W. Kim, M. C. Wei, S. Yin, J. Sit, S. Tracy, F. Sabalvaro, E. Penuel, L. E. Budde

Get full text